<DOC>
	<DOCNO>NCT01162681</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability three different dos A-623 administer addition standard therapy subject active SLE disease</brief_summary>
	<brief_title>PEARL-SC Trial : A Study Efficacy , Safety , Tolerability A 623 Administration Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Diagnosis SLE American College Rheumatology guideline . On stable SLE treatment Active SLE disease Serologically active 18 year age old Receiving stable dos prednisone 7.5 mg 40 mg per day Severe active vasculitis , active central nervous system lupus , active lupus nephritis , uncontrolled hypertension , uncontrolled diabetes . Known positive HIV and/or positive screen visit hepatitis B , hepatitis C. Liver disease . Anemia , neutropenia , thrombocytopenia . Malignancy within past 5 year Active infection require hospitalization treatment parenteral antibiotic within past 60 day history repeat herpetic viral infection . History active tuberculosis history tuberculosis infection . Participation active treatment arm Phase 2 Phase 3 clinical trial molecule primarily target B cell pathway past 18 month . Prior administration B cell deplete therapy past 18 month . Pregnant nursing History congenital immunodeficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>SLE</keyword>
	<keyword>Lupus</keyword>
	<keyword>Lupus Erythematosus , Systemic</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>A-623</keyword>
	<keyword>Blisibimod</keyword>
</DOC>